Latest Security News

Tartana Minerals has postponed its planned drilling at the Beefwood copper-gold prospect in Far North Queensland due to persistent wet conditions, resulting in the loss of government funding and a rescheduled timeline for 2026.

Mammoth Minerals has raised A$7.5 million through a placement to accelerate exploration at its high-grade Excelsior and Bella Gold Projects in Nevada, aiming to unlock significant gold potential.

Polymetals Resources has raised $34.4 million through a share placement to boost exploration and production at its Endeavor Silver Zinc Mine, attracting strong institutional demand.

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.

Chariot Resources has amended its acquisition agreement for a Nigerian lithium portfolio, securing financing and extending the closing deadline to May 2026. The move reinforces exclusivity protections and paves the way for a smoother transaction completion.

White Cliff Minerals has identified multiple high-priority copper targets along the 10km Teshierpi Fault Zone at its Rae Copper Project in Nunavut, Canada, following a comprehensive 2025 airborne electromagnetic survey. The findings extend known mineralisation at Danvers and set the stage for follow-up drilling in early 2026.

Prairie Lithium has completed critical groundwork at its Canadian lithium brine project, setting the stage for construction and commercial operations in 2026 amid rising lithium prices.

Transurban Group has announced a 34.0 cents per stapled security interim distribution for the half-year ending December 2025, maintaining its FY26 distribution guidance at 69.0 cents. The Distribution Reinvestment Plan will operate without a discount, signaling steady confidence amid ongoing macroeconomic uncertainties.

Microba Life Sciences has secured a $3.06 million R&D tax incentive refund for FY25, reinforcing its cash reserves and supporting ongoing advancements in gastrointestinal diagnostics and clinical therapeutics.

Transurban Group has announced a 34-cent unfranked dividend per stapled security for the six months ending December 2025, alongside a Dividend Reinvestment Plan with no discount.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Island Pharmaceuticals has secured over $1 million through option exercises by directors and major shareholders, bolstering its cash reserves to advance the clinical and regulatory development of its broad-spectrum antiviral, Galidesivir.